Compare AbbVie Inc (ABBV) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Star Bulk Carriers Corp — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Star Bulk Carriers Corp trades at $26.44 (market cap $2.92B). The key difference: AbbVie Inc is far larger — about 154.1× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (3.93%). Which is the better fit depends on your goals.
| ABBV | SBLK | |
|---|---|---|
Market Cap | $449.91B | $2.92B |
Sector | Health | Industrials |
52-Week High | $261.07 | $28.21 |
52-Week Low | $184.85 | $16.79 |
Enterprise Value | $513.38B | $3.62B |
Dividend Yield | 2.72% | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
Star Bulk Carriers (SBLK) trades at $26.12, up 3.86% with bullish technical signals and strong earnings momentum after beating Q1 2026 estimates. The company shows solid fundamentals with 13.01% net income margin and positive cash flow, supported by a new dividend policy returning 100% of free cash flow. Analyst consensus is strongly bullish with 14 buy ratings.
SBLK presents a compelling investment case with earnings growth acceleration and shareholder-friendly capital allocation. Key risks include dry bulk market volatility and oil price sensitivity, but strong institutional support and technical momentum suggest continued upside potential for disciplined investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
